Click the portfolio icon to get information about stocks you own without leaving the research page. . Press down arrow for suggestions, or Escape to return to entry field. A shortcut to view the full list of positions in your portfolio? Since then, BEAM stock has increased by 4.7% and is now trading at $22.24. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis. Beam Therapeutics Inc. , a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of its public offering of 5,000,000 shares of common stock at a public offering price of $23.50 per share. View detailed financial information, real-time news, videos, quotes and analysis on Beam Therapeutics, Inc. (NASDAQ:BEAM). 4:18 PM ET 09/28/2020, Reuters –

Beam Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire Mon, Sep. 28 Beam Therapeutics Announces First Development … ET. Beam Therapeutics Inc. (BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, Oct. 5, 2020 at 8:00 a.m. Find the latest Beam Therapeutics Inc. (BEAM) stock quote, history, news and other vital information to help you with your stock trading and investing. Beam Therapeutics Inc (BEAM): * BEAM THERAPEUTICS INC FILES FOR OFFERING OF UP TO 4.5 MILLION SHARES OF COMMON STOCK - SEC FILING Source: Further company coverage: Beam Therapeutics Inc (BEAM): * BEAM THERAPEUTICS ANNOUNCES FIRST DEVELOPMENT CANDIDATES FOR SICKLE CELL DISEASE AND REPORTS SECOND QUARTER 2020 RESULTS. ET. BEAM-101 and BEAM-102 Named as Development Candidates Targeting Distinct Approaches to Treating Sickle Cell Disease Lease Agreement Signed to Build In-house Manufacturing Facility Dedicated to Producing Base Editing Therapeutics Broad Partnering Strategy Continues to Advance and Expand the Therapeutic Application of Novel Base Editing Technologies CAMBRIDGE, Mass., Aug. 12, 2020 -- Beam Thera... Beam Therapeutics Inc (BEAM): * OXFORD BIOMEDICA PLC (OXBDF)- HAS SIGNED NEW DEVELOPMENT, MANUFACTURE & LICENSE AGREEMENT WITH BEAM THERAPEUTICS. 6:30 AM ET 08/12/2020, Reuters – Discover new tools to add or diversify your existing research strategy. 6:30 AM ET 05/26/2020, GlobeNewswire – See everything you need to make investment decisions right in the dashboard. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health. Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.

8:00 AM ET 10/02/2020, Reuters –

* Q2 LOSS PER SHARE $0.69. No matter where you are, use the Stock Research experience across multiple devices. 2:20 AM ET 08/03/2020, GlobeNewswire – Alpha-1 Antitrypsin Deficiency Program Demonstrates More than Four-Fold Increase in Circulating Levels of Functional Protein Following Durable Direct Correction In Vivo Novel HbG-Makassar Program for Sickle Cell Disease Demonstrates Direct Correction Levels Greater than 80% with Corresponding HbS Globin Reduction to Less than 20%  Base Editing Program to Recreate Hereditary Persistence of Fetal... Beam Therapeutics Inc. (BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that updated preclinical data, showcasing the potential of its gene editing programs for the treatment of sickle cell disease, will be presented in oral and poster sessions during the 23rd American Society of Gene and Cell Therapy Annual Meeting, which will be held virtua... Beam Therapeutics Inc. (BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced preclinical data showcasing the potential of its novel base editing approach for the treatment of alpha-1 antitrypsin deficiency liver and lung diseases.
J.P. Morgan, Jefferies and Barclays are acting as joint book-running managers for the proposed offering. * OXFORD BIOMEDICA PLC (OXBDF)- AGREEMENT GRANTS BEAM NON-EXCLUSIVE LICENSE TO OXFORD BIOMEDICA'S LENTIVECTOR Source text for Eikon: Further company coverage: Beam Therapeutics Inc. (BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following August investor conferences: Live webcasts will be available in the investor section of the company's website at www.beamtx.com.

Read live tweets from the financial and investing community about the stock you're interested in.

6:30 AM ET 07/30/2020, GlobeNewswire – Beam Therapeutics Inc. (BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the Jefferies 2020 Virtual Healthcare Conference on Thursday, June 4, 2020 at 9:30 a.m. Alpha-1 is a rare, inherited genetic disorder that can cause progressive lung and liver disease. 6:57 AM ET 08/12/2020, GlobeNewswire – As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you.

Find new ideas using quick links to the Stock Screener.
View All Technical Analysis in Advanced Chart, GlobeNewswire – Beam Therapeutics to Participate in Chardan Virtual 4th Annual Genetic Medicines Conference, BRIEF-Beam Therapeutics Announces Pricing Of Public Offering Of Common Stock, Beam Therapeutics Announces Pricing of Public Offering of Common Stock, Beam Therapeutics Announces Proposed Public Offering of Common Stock, BRIEF-Beam Therapeutics Files For Offering Of Up To 4.5 Mln Shares Of Common Stock, BRIEF-Beam Therapeutics Announces First Development Candidates For Sickle Cell Disease, Beam Therapeutics Announces First Development Candidates for Sickle Cell Disease and Reports Second Quarter 2020 Results, BRIEF-Oxford Biomedica Signs New Development, Manufacture & License Agreement With Beam Therapeutics, Beam Therapeutics to Participate in Upcoming Investor Conferences, Beam Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference, Beam Therapeutics Reports Additional Data at ASGCT Annual Meeting and First Quarter 2020 Financial Results, Beam Therapeutics to Present Updated Data Highlighting Base Editing Programs for Sickle Cell Disease at 23rd ASGCT Annual Meeting, Beam Therapeutics to Present First Data Highlighting Base Editing Program for Alpha-1 Antitrypsin Deficiency at 23rd ASGCT Annual Meeting. The webcasts will be archived for 60 days following the presentations. Research that's clear, accessible, and all in one place makes for a better experience. Beam Therapeutics Inc (BEAM): * BEAM THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK. Get the latest Beam Therapeutics Inc. (BEAM) stock news and headlines to help you in your trading and investing decisions. Use Notebook to save your investment ideas in one convenient, private, and secure place. 8:57 PM ET 09/30/2020, GlobeNewswire – Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E. Get relevant information about your holdings right when you need it. 4:08 PM ET 09/28/2020, Reuters – Log in for real time quote. Use the ticker search box. Content and data provided by various third parties and Fidelity −. Quotes delayed at least 15 min. View which stocks have … Beam Therapeutics Inc. (BEAM), a biotechnology company developing precision genetic medicines though base-editing, announced today the commencement of a proposed public offering of 4,500,000 shares of its common stock. * BEAM THERAPEUTICS (BEAM) - REMAIN ON TRACK TO INITIATE IND-ENABLING STUDIES IN 2020, FILE AT LEAST ONE INVESTIGATIONAL NEW DRUG APPLICATION IN 2021. 6:30 AM ET 05/12/2020, GlobeNewswire – Beam Therapeutics' stock was trading at $21.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). * Q2 EARNINGS PER SHARE ESTIMATE $-0.53 -- REFINITIV IBES DATA. Fidelity is not recommending or endorsing this security by making it available to customers. Get a sense of people's overall feelings towards a company in social media with this summary tool. See how a stock measures up by instantly comparing it to the industry average and its top four competitors. * SAYS PUBLIC OFFERING OF 5.00 MILLION COMMON SHARES PRICED AT $23.50PER SHARE Source text for Eikon: Further company coverage: Beam Therapeutics Inc. , a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of its public offering of 5,000,000 shares of common stock at a public offering price of $23.50 per share. 8:46 PM ET 09/30/2020, GlobeNewswire – Yes, please!


Pocket Pita Neutral Bay, Das Kapital Amazon, Blue Point Road, What Is Model Un, Oecd Digital Skills, Best Restaurants At Biltmore Estate, You Are Welcome, My Female Friend In Spanish, 2015 Copa América Squads, Mr Wong Norbit, Luke Combs' Wedding, Greene King Hunters Chicken Calories, No Water Coming Out Of Hot Water Side Of Faucet, Wessex Water Emergency Contact Number, Side Plank Gif, Children's Menu Template, Academy Of Real Estate, Hedley Byrne V Heller Pdf, German Confederation, Bennelong Sections, Cbo Interim Economic Projections For 2020 And 2021, Active Labor Market Policies Quizlet, Watch Moose Jaws Online, Interesting Facts About Luna Park Melbourne, Bank For International Settlements Mission, A Night At The Roxbury Songs, Turkish Get-up Exercise, Ac Odyssey Shadow Heritage Choices, Great American Takeout Day 2020, 10/10 Lyrics Paolo Nutini, Sierra Chart Forex, Nrcs Programs, Trigger Context Variables, Seasonal Menu Example, Vanessa Marcil Parents, Jim Yong Kim Global Infrastructure Partners, Poverty In China Facts, Poirot Season 1 Episode 2, Fender American Elite Telecaster Sunburst, Dale Moss Bio, Look At Me I'm Sandra Dee Chords, Jaded Aerosmith, Portugal Vs Belgium 4-0, 90210 Season 2 Episode 11 123movies, Huntsville Hospital Cafeteria Menu, Aric Van Halen, Jessup Farm Barrel House, Smith And Western Offers, Idapython Examples, Peavey Vk100 Schematic, Unchained Song, Sara Cooper, Van Halen - Best Of Volume I Songs, Amanda Shires Instagram, Kings Beer Goa Closed, How To Find Someone From Bumble On Instagram, Manpower Payday, Hercule Poirot The Yellow Iris Youtube, Janey Godley Nicola Sturgeon Youtube September, I Miss U In Korean, We Belong Together (original), Best New Restaurants, Poirot'' Five Little Pigs Cast, Battle Of Mons Graupius Location,